- Home
- PDI vs RYTM Comparison
PDI vs RYTM Comparison
Compare PDI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDI
- RYTM
- Stock Information
- Founded
- PDI 2012
- RYTM 2008
- Country
- PDI United States
- RYTM United States
- Employees
- PDI N/A
- RYTM 283
- Industry
- PDI Trusts Except Educational Religious and Charitable
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- PDI Finance
- RYTM Health Care
- Exchange
- PDI Nasdaq
- RYTM Nasdaq
- Market Cap
- PDI 7.3B
- RYTM 6.9B
- IPO Year
- PDI N/A
- RYTM 2017
- Fundamental
- Price
- PDI $20.03
- RYTM $102.12
- Analyst Decision
- PDI
- RYTM Strong Buy
- Analyst Count
- PDI 0
- RYTM 13
- Target Price
- PDI N/A
- RYTM $101.92
- AVG Volume (30 Days)
- PDI 1.5M
- RYTM 550.8K
- Earning Date
- PDI 01-01-0001
- RYTM 11-04-2025
- Dividend Yield
- PDI 13.81%
- RYTM N/A
- EPS Growth
- PDI N/A
- RYTM N/A
- EPS
- PDI N/A
- RYTM N/A
- Revenue
- PDI N/A
- RYTM $156,287,000.00
- Revenue This Year
- PDI N/A
- RYTM $44.69
- Revenue Next Year
- PDI N/A
- RYTM $63.53
- P/E Ratio
- PDI N/A
- RYTM N/A
- Revenue Growth
- PDI N/A
- RYTM 53.55
- 52 Week Low
- PDI $15.45
- RYTM $45.91
- 52 Week High
- PDI $19.60
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- PDI 86.19
- RYTM 60.62
- Support Level
- PDI $19.43
- RYTM $101.45
- Resistance Level
- PDI $19.49
- RYTM $106.52
- Average True Range (ATR)
- PDI 0.09
- RYTM 3.12
- MACD
- PDI 0.07
- RYTM -0.43
- Stochastic Oscillator
- PDI 97.06
- RYTM 65.84
About PDI PIMCO Dynamic Income Fund
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investments include mortgage-backed securities, investment grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.